Calotatug Biosimilar - Research Grade

Human

ERBB2

>1mg/ml

IgG1 - kappa

CHO Cells

Trastuzumab Biosimilar - Research Grade (ICH4013), Ado-Trastuzumab Emtansine Biosimilar - Research Grade (ICH4014), Pertuzumab Biosimilar - Research Grade (ICH4030), Margetuximab Biosimilar - Research Grade (ICH5057), Anbenitamab Biosimilar - Research Grade (ICH5344), Coprelotamab Biosimilar - Research Grade (ICH5448), Disitamab Biosimilar - Research Grade (ICH5482), Gancotamab Biosimilar - Research Grade (ICH5562), Lunaxafusp Biosimilar - Research Grade (ICH5662), Timigutuzumab Biosimilar - Research Grade (ICH5925), Zanidatamab Biosimilar - Research Grade (ICH6002)

https://www.imgt.org/mAb-DB/

ICH3002

P04626

Blue ice

ICH5421 is a research-grade biosimilar of Calotatug, supplied as an unconjugated, non-therapeutic analog of the originator antibody and built around its target antigen, ERBB2 (HER2). It is a human IgG1, kappa molecule intended strictly for research use (RUO) and is not a clinical drug. The material is produced to in-vivo research standards with low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg options) and is available in bulk mg to gram quantities, making it suitable for assay standardization, method development, and comparative studies. As a biosimilar reagent it reproduces the binding specificity of the originator against HER2 without carrying any therapeutic claim, so it functions as a defined, reproducible tool for characterizing HER2 biology and benchmarking other anti-HER2 reagents. Because it is a human-targeting IgG1, it is most commonly deployed in functional and in-vitro contexts rather than mouse dosing studies. Investigators typically use it as a positive control, a reference binder, or a probe in HER2-focused experimental systems where a consistent, well-characterized antibody is needed. ERBB2 (HER2/neu, UniProt P04626) is a member of the epidermal growth factor receptor (ErbB/HER) family of receptor tyrosine kinases. Unlike its family members, HER2 has no known high-affinity soluble ligand; instead it acts as the preferred heterodimerization partner for ligand-bound EGFR, HER3, and HER4. Dimerization activates its intracellular kinase domain and drives downstream RAS-MAPK and PI3K-AKT signaling, promoting proliferation, survival, and differentiation. HER2 is amplified or overexpressed in a subset of breast, gastric, and other epithelial cancers, where it is a validated oncogenic driver and a well-established therapeutic and diagnostic target. Its extracellular region comprises four subdomains that are the focus of antibody recognition and of engineered anti-HER2 binders. HER2's clear surface expression and clinical relevance make it a frequent subject of binding, neutralization, and receptor-biology studies.

Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, Receptor tyrosine-protein kinase erbB-2, HER2, NEU, NGL

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Calotatug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Calotatug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Calotatug biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Calotatug that binds ERBB2; for research use only.